June

OriCell Therapeutics reported Phase 1 study data of Ori-CAR017 in oral presentation at ASCO annual meeting 2022

May

OriCell Therapeutics's CAR-T clinical data accepted for presentation at 2022 European Hematology Association 2022 Congress

OriCell selected in Shanghai Professional, Refined, Specialized, Novel Businesses List

April

OriCell CAR-T Product Ori-CAR-017 Clinical Data Abstract Selected for Oral Presentation at ASCO 2022

March

OriCell announced the appointment of Dr. Weidong Cui as Chief Technology Officer

November and October

OriCell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for poster presentation at the 2021 CSCO Annual Meeting

September 25

OriCell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for an oral presentation at the 2021 CSCO Annual Meeting

September

OriCell Therapeutics was the responsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality

August

OriCell Therapeutics was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality

June 7

The first CAR-T cell product targeting liver cancer developed by OriCell Therapeutics made its debut at ASCO

May

OriCell Medical Technology Co., Ltd. officially changed its name to "OriCell Therapeutics (Shanghai) Co., Ltd."

December

OriCell Medical received the A round of financing of 202.138 million, an investment led by SPINNOTEC, Zhangjiang Technology Venture Capital, and Yijing Capital, followed by Qiming Venture Partners and Osen Assets

OriCell Medical established the Shanghai Academician (Expert) Workstation

November

OriCell Medical established the Pudong New Area Enterprise Postdoctoral Research Workstation Substation

October

OriCell Medical won the first prize in the 13th "Zhangjiang Pharma Valley Cup" Biomedicine Experimental Skill Competition

June

OriCell Medical was the responsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality

OriCell Medical reached a global development agreement regarding the independently-developed bispecific antibody with ANTENGENE (6996.HK), with a potential worth of 142 million USD

December

OriCell Medical received the pre-A round of exclusive funding from Qiming Venture Partners

November

OriCell Medical became a co-construction unit of Shanghai Cell Therapy Clinical Transformation Engineering Technology Center

OriCell Medical became one of the funded key technology start-up enterprises in Pudong New Area

April

OriCell Medical was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality

November

OriCell Medical was recognized as a High- and New-Technology Enterprise

OriCell Medical received funding from the 2018 Pudong New Area Science and Technology Development Fund

The Secretary-General of the Nobel Prize Committee visited OriCell Medical

October

OriCell Medical attended the 2018 Chinese Conference on Translational Medicine and presented its independent R&D results in multiple fields

June

OriCell Medical's research results for CAR-T in liver cancer were published in the authoritative journal Protein & Cell

May

OriCell Medical signed a strategic cooperation agreement with an emerging enterprise in the domestic CAR-T industry, Beijing Yimiaoshenzhou Medical Technology Co., Ltd.

March

The Ministry of Science and Technology approved OriCell Medical as the principal institution to continue and complete the research project of the 973 Program titled "Research on New Intervention Strategies for Ankylosing Spondylitis"

July

OriCell Medical in collaboration with Zhongshan Hospital carried out a series of clinical trials of the cell therapy technologies (among which CAR-T was the most notable) at the Zhongshan-OriCell Therapy Center, which was jointly constructed by the two units

May

Shanghai Changzheng Hospital and OriCell Medical joined hands again and established the "Changzheng - OriCell Clinical Research Center" at Shanghai Changzheng Hospital

May

OriCell Medical established the CAR-T technology platform with high memory and high vitality

February

OriCell Medical expanded its R&D team

February

OriCell Medical was founded by OriCell Group; the co-founder Dr. He Xiaowen served as the chief scientist